Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BTCY
Biotricity Inc. (BTCY) EV/Sales
As of 16 October 2026, Biotricity Inc. (BTCY) trades at a EV/Sales of 1.7×. Over the past ten years it has ranged from 0.0× (March 2019) to 84.3× (April 2019); the current reading is higher than 29% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.1× | (11.24%) |
| FY2025 | 2.3× | (18.72%) |
| FY2024 | 2.9× | (33.31%) |
| FY2023 | 4.3× | (68.74%) |
| FY2022 | 13.7× | (49.61%) |
| FY2021 | 27.3× | 6.96% |
| FY2020 | 25.5× | (67.47%) |
| FY2019 | 78.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.8× | (14.51%) |
| Mar 2026 | 2.1× | (7.61%) |
| Dec 2025 | 2.2× | (14.70%) |
| Sep 2025 | 2.6× | 8.03% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AEMD Aethlon Medical, Inc. compare | −2.8× |
| RBOT Vicarious Surgical Inc. compare | n/m |
| IRIX IRIDEX Corporation compare | 0.3× |
| NMTC NeuroOne Medical Technologies Corporation compare | 0.7× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| BMRA Biomerica, Inc. compare | 0.9× |
| BTCY Biotricity Inc. | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. compare | 3.7× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)